Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017

Pink Sheet Perspectives 2017 - 2018

Related Content

Opioid Warning Letter To Cipher Likely Easy Call For US FDA

Sep 06 2017

Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads

Aug 19 2017

PhRMA Seeks US FDA Rationale For Rx Drug Advertising Studies

Aug 29 2017

Contrave TV Ad's Slimmed Down Adverse Events Draw FDA Rebuke

May 25 2017

FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations

Jun 01 2017

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Jul 10 2017

Off-Label Communication: When Does It Align With Approved Labeling?

Jan 18 2017

FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized

Jan 09 2017

Don't Sleep On DTC Compliance: FDA Dings Zolpimist Superiority Claim Vs Ambien

Nov 24 2017

Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study

Dec 12 2017

Related Companies

Amherst Pharmaceuticals, LLC

Cipher Pharmaceuticals Inc.

Orexigen Therapeutics, Inc.

Additional Topics

United States Regulation FDA Advertising, Marketing & Sales BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window